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Purpose. The aims were to correlate individual marrow metabolic changes after chemotherapy with bone marrow biopsy (BMBx)
for its potential value of personalized care in lymphoma. Methods. 26 patients (mean age, 58 ± 15 y; 13 female, 13 male) with
follicular lymphoma or diﬀuse large B-cell lymphoma, referred to FDG-PET/CT imaging, who had BMBx from unilateral or
bilateral iliac crest(s) before chemotherapy, were studied retrospectively. The maximal standardized uptake value (SUV) was
measured from BMBx site over the same area on both initial staging and first available restaging FDG-PET/CT scan. Results.
35 BMBx sites in 26 patients were evaluated. 12 of 35 sites were BMBx positive with interval decrease in SUV in 11 of 12 sites
(92%). The remaining 23 of 35 sites were BMBx negative with interval increase in SUV in 21 of 23 sites (91%). The correlation
between SUV change over the BMBx site before and after chemotherapy and BMBx result was significant (P < 0.0001). Conclusions.
This preliminary result demonstrates a strong correlation between marrow metabolic changes (as determined by FDG PET)
after chemotherapy and bone marrow involvement proven by biopsy. This may provide a retrospective means of personalized
management of marrow involvement in deciding whether to deliver more extended therapy or closer followup of lymphoma
patients.
1. Introduction
Molecular imaging using 2-deoxy-2-[F-18]fluoro-d-glucose
(FDG) positron emission tomography (PET) scanning has
recently emerged as a major imaging modality for the staging
and followup of patients with non-Hodgkin’s lymphoma
(NHL) [1, 2]. Diﬀuse large B-cell lymphoma is the most
common subtype. Follicular lymphoma accounts for 22%
of NHL in adults with high tendency to involve the bone
marrow [3, 4]. Follicular grade I lymphoma is the most
predominating histological subtype to involve the marrow
[5]. Before initiation of treatment, distinguishing potentially
curable (stage I/II) from advanced disease (stage III/IV) may
guide the planning of management. The advanced stages
III and IV correlate significantly with shorter overall or
event-free survival, and treatment may have to be modified
accordingly. In NHL, bone marrow involvement places the
patient in the advanced disease (stage IV). Bone marrow
biopsy (BMBx) is the established method for detection of
bone marrow involvement in the initial staging and restaging
of NHL. However, BMBx is a painful and invasive procedure
and sometimes only a small sample can be obtained, which
may be inconclusive due to sampling errors, despite bilateral
iliac crest blind biopsy under anesthesia. Furthermore, even
if the volume of the biopsy is adequate, focal lesions may
be missed. Thus, although it is very specific, BMBx from
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traditional biopsy sites (iliac crests) has low sensitivity in
detecting marrow involvement of lymphoma. It is essential
to have a supplementary prospective, and if not possible
even retrospective diagnostic procedure, possibly consisting
of a multistep approach, to reliably assess bone marrow
infiltration in patients with NHL to compliment the BMBx.
The ability of FDG-PET to evaluate bone marrow infil-
tration in patients with lymphoma has been investigated
extensively. Multiple prior studies showed that FDG-PET
has a high potential to detect bone marrow involvement
in high-grade malignant lymphoma with low sensitivity
for the detection of bone marrow infiltration in low-grade
NHLs [6, 7] despite the fact that bone marrow involvement
occurs in 30%–50% of patients with NHL. The majority
of these studies used visual interpretation of marrow FDG
uptake during whole-body staging PET scans to assess bone
marrow involvement. Since it is more common in indolent
histology [8, 9], the marrow activity may be not avid for
visual detection based on a single staging PET scan. In the
visual approach, the marrow was assumed to be abnormal
where the FDG uptake was equal to or greater than uptake
in the liver, which was usually greater than background.
This approach for assessing marrow involvement depends
on the extent of marrow infiltration by lymphoma and
has made no use of available information from pre- and
postchemotherapy intramedullary metabolic activities due
to changes in cell population.
The standardized uptake value (SUV) is a semiquantita-
tive measure of the glucose metabolism based on the degree
of FDG uptake, which is derived from the tumor activity
divided by dose per body mass in the attenuation-corrected
PET images [10]. It may improve the definition of abnormal
areas by reducing subjective assessment. It is common to
see the pattern of diﬀusely increased FDG uptake in normal
bone marrow after chemotherapy on F-18 FDG-PET scans
due to change in hematopoietic cell population. Decreased
FDG uptake after chemotherapy is noted in the areas with
PET evidence of bone marrow involvement due to reduction
in tumor population. The aims were to correlate individual
marrow metabolic changes after chemotherapy with bone
marrow biopsy (BMBx) for its potential value of personalized
care in lymphoma.
2. Materials and Methods
Database of patients referred for FDG-PET/CT scan for
initial staging and first restaging after chemotherapy who
had BMBx from unilateral or bilateral iliac crest(s) before
chemotherapy at a tertiary hospital and cancer center over a
period of two years was retrospectively searched with Human
Investigation Committee approval. Patients were excluded if
they had malignancies other than lymphoma or if they had
received prior radiation treatment or chemotherapy. Twenty-
six patients were eligible for this study. The mean age was 58
± 15 years old with 13 females and 13 males. There were 16
follicular lymphomas (FL, grades I, II, and III) and 10 diﬀuse
large B-cell lymphomas (DLBC). The maximal standardized
uptake value (SUV) was measured from BMBx site over the
same area on both initial staging and restaging FDG-PET/CT
scans. The interval changes of SUVwere classified as decrease
or increase and correlated with BMBx result of positive or
negative for bone marrow involvement by lymphoma.
PET-CT imaging was obtained by a dedicated 16-slice
body PET-CT scanner (GE Discovery DST, GE Medical
Systems, Milwaukee, Wis, USA). All patients had fasted for
4 to 6 hours before the intravenous injections of average of
15mCi (555 MBq) F-18 FDG. PET scans were performed
around one and a half hours after injection right after
mapping CT. This choice of FDG uptake time was based
on the modified schedule of usual one-hour time of FDG
uptake to maximize the contrast between tumor, soft tissue,
and benign inflammation if any [11]. The PET images were
obtained at each bed position for 3 minutes with 6–8 beds to
cover the entire body. The PET images were obtained using
a two-dimensional high-sensitivity mode with an axial field
of view of 15 cm in a 256 × 256 matrix. A 3-slice overlap
was utilized between the bed positions. The PET images
were reconstructed iteratively on a 128 × 128 matrix using
ordered-subsets expectation maximization algorithm for 30
subsets and two iterations, with a 7.0mm postreconstruction
filter. An initial scout scan was obtained first to define the
imaging field for the CT component of image acquisition,
which used the following imaging parameters: 140 kVp,
120–200mA, 0.8 seconds per CT rotation, pitch 1.75 : 1, and
detector configuration of 16× 1.25mm, 3mm slice thickness
with oral contrast only.
The serum glucose in mg/dL was recorded just before
PET, and the maximum SUV, defined as tumor activity
divided by dose injected per body mass, was measured by
searching the maximum value within a volume of inter-
est over BMBx sites (posterior iliac crests) by a nuclear
medicine physician. Bone marrow involvement was defined
by histopathologically proven bone marrow lymphoma
infiltration from marrow biopsy. Statistical analysis was
done using SPSS (SPSS Inc, Chicago, IL) for comparing the
changes of marrow before and after chemotherapy. A P value
of <0.05 was considered significant in all tests.
3. Results
Thirty-five BMBx sites from 26 patients were evaluated.
Twelve of 35 sites were BMBx positive with interval decrease
in SUV in eleven out of the 12 sites (92%) (Figure 1). For the
11 sites with true positive PET findings (decreased SUV on
BMBx positive sites), the magnitude of SUV decrease ranged
from 0.7 to 15.8 (−27 to −89%) for an average 8.3 ± 5.9
(−64 ± 24%).
The remaining twenty-three of 35 sites were BMBx
negative with interval increase in SUV in 21 of 23 sites (91%)
(Figure 2). In the 21 sites with true negative PET results
(increased SUV on BMBx negative sites), the range of SUV
increase was from 0.1 to 9.2 (+5 to +575%), average 1.7 ±
2.0 (+106 ± 128%).
The correlation between SUV change over the BMBx
site before and after chemotherapy and BMBx result was
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Figure 1: 53-year-old female with follicular grade 3 lymphoma with clear marrow involvement (a). This patient had bilateral iliac marrow
biopsy. The post-treatment PET-CT (b) shows diﬀuse uniform increase in marrow uptake. However, the SUV actually decreases (from
6.7 to 4.9) on the right iliac bone marrow with pathologic confirmation of marrow involvement (b). On the contrary, the SUV over the
pathologically negative left iliac bone marrow increases (from 2.7 to 4.2) due to normal hematopoietic response.
significant (P < 0.0001). The interval between chemotherapy
and restaging PET scan was 9 to 75 days (mean 22± 16 days).
The interval between BMBx and initial staging PET scan was
1 to 47 days (mean 8 ± 9 days).
4. Discussion
It is currently a common practice to use PET scan as a quali-
tative tool in the arena of lymphoma, supplemented by more
clinically useful information extracted in the form of SUV,
to aid in therapeutic decision making and prognostication.
The clinical significance of the current study suggested that
change in marrow SUV measurement after chemotherapy
might provide a retrospective marrow staging, which may
give the same information noninvasively as obtained from
traditional BMBx regarding bone marrow involvement of
lymphoma.
Bone marrow involvement in patients with lymphoma
signifies extensive disease with less favorable prognosis.
Although bone marrow biopsy is still the gold standard
method for detection of bone marrow involvement in the
initial staging or restaging of lymphomas, the potentially low
sensitivity and invasive nature as well as other limitations of
marrow biopsy make it nonideal diagnostic test in detection
of marrow infiltration. A more reliable and sensitive nonin-
vasive method of detecting marrow involvement would be
desirable. FDG-PET imaging has become a major imaging
modality for the staging and followup of patients with NHL
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Figure 2: 58-year-old female with follicular grade 3 lymphoma (a) without focal evidence of marrow involvement by PET. She had right
iliac biopsy. The posttreatment PET-CT (b) again shows diﬀuse increase in marrow uptake. The SUV increases (from 1.7 to 3.8) on the right
iliac bone marrow (red region) with pathologic examination negative for marrow involvement. The change of the SUV over bone marrow is
all due to normal hematopoietic response to chemotherapy.
[1, 2], and the potential ability of FDG-PET to evaluate both
focal and diﬀuse bone marrow infiltration in patients with
lymphoma is a natural choice for investigation and optimiza-
tion. Though prior studies with pure visual interpretation of
marrow FDG uptake to assess marrow have revealed a high
potential to detect bone marrow involvement in malignant
lymphoma [12–14], the sensitivity is still unacceptably low in
low-grade non-Hodgkin’s lymphomas [6, 7, 15]. The present
study was undertaken to investigate and optimize the eﬃcacy
of FDG-PET as a potentially improved and complimentary
method to aid in evaluating marrow involvement in patients
for personalized care of lymphomas by utilizing individual
interval metabolic changes instead of detection of focal
abnormal marrow uptake based on a single staging PET scan
alone.
The strong correlation between SUV change after chemo-
therapy and BMBx result as demonstrated from this current
study has notable potential clinical significance. PET-CT is
more sensitive than marrow biopsy and can be employed
routinely to assess the entire marrow [16]. In patients
with initial obvious focal FDG-avid bone marrow lesions,
FDG-PET may oﬀer guidance to biopsy or can be used
as direct evidence of bone marrow involvement. The bone
marrow involvement of these lesions can be confirmed by
analyzing SUV changes after chemotherapy. If initial FDG
PET shows no definite focal marrow lesions and patient
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needs chemotherapy clinically, then the retrospective analysis
of SUV changes after chemotherapy over the traditional
BMBx sites may oﬀer similar if not better information as
obtained from BMBx regarding bone marrow involvement
by lymphoma and therefore potentially eliminate the error
onmanagement caused by false negative pretreatment BMBx
due to sampling issue. Whether a blind marrow biopsy
may still be warranted in patients with indolent lymphoma
for whom chemotherapy may not be oﬀered if there is
no evidence of bone marrow involvement by lymphoma,
or in patients with marrow population changes related to
factors other than chemotherapy only, for example, G-
CSF treatment, bone marrow dysplasia, prior chemo- or
radiation treatment, and so forth, needs further clinical
investigation. Nonetheless, the current study moves a step
towards personalized care by employing retrospective evi-
dence of marrow involvement in lymphoma patients. Since
the current revised response criteria for lymphoma require
clearance of infiltrative marrow lesions by repeated biopsy
[17], the current study may oﬀer an alternative insight for
noninvasive marrow response criteria by requiring involved
marrow sites to show decrease in SUV from hot or normal
FDG uptake to reduced or cold metabolic activity on the
marrow.
With PET-CT, the functional PET images are coregistered
with the anatomic CT images obtained by the almost
simultaneously acquired CT scan. This approach can result
in a significant improvement in the accurate anatomic
localization and the region of interest determination and
therefore make sure that the measurement of SUV is over
the same area before and after chemotherapy. The current
study demonstrates that the change in metabolic behavior
correlates well with marrow cell population change and
suggests possible optimization of metabolic information
by using intramedullary SUV change to countercheck or
supplement the invasive limited sampling of histological
examination to predict marrow involvement, which in turn
may lead to the most appropriate subsequent management
for each individual patient.
There are limitations of this current retrospective study,
including small sample size, mixed histopathological clas-
sification, and significant variation of interval between
chemotherapy and restaging PET scan. A comparison
between bone marrow biopsy and evaluations of FDG-
PET after treatment is not accomplished. This is partially
because there will be little justification to repeat biopsy
if there is already a good response to therapy. A well-
designed prospective study overcoming the above limitations
to further confirm the conclusion of this preliminary study is
necessary and is currently being investigated.
5. Conclusion
This preliminary study demonstrates a strong correlation
between marrow metabolic changes by FDG PET scan
after chemotherapy and marrow cell population change.
There is an inverse relationship between (positive) marrow
involvement of lymphoma and SUV change (decrease) after
chemotherapy. The potential clinical significance of this
observation is to provide a noninvasive retrospective means
of countercheck or replacement of the invasive limited
sampling of histological examination in predicting marrow
involvement, which in turn may help in personalized care of
deciding whether to deliver more extended therapy or closer
followup of lymphoma patients.
References
[1] R. Kumar, I. Maillard, S. J. Schuster, and A. Alavi, “Utility
of fluorodeoxyglucose-PET imaging in the management of
patients with Hodgkin’s and non-Hodgkin’s lymphomas,”
Radiologic Clinics of North America, vol. 42, no. 6, pp. 1083–
1100, 2004.
[2] C. Burton, P. Ell, and D. Linch, “The role of PET imaging in
lymphoma,” British Journal of Haematology, vol. 126, no. 6, pp.
772–784, 2004.
[3] The Non-Hodgkin’s Lymphoma Classification Project, “A
clinical evaluation of the international lymphoma study group
classification of non-Hodgkin’s lymphoma,” Blood, vol. 89, no.
11, pp. 3909–3918, 1997.
[4] P. Lu, “Staging and classification of lymphoma,” Seminars in
Nuclear Medicine, vol. 35, no. 3, pp. 160–164, 2005.
[5] D. A. Arber and T. I. George, “Bone marrow biopsy involve-
ment by non-Hodgkin’s lymphoma: frequency of lymphoma
types, patterns, blood involvement, and discordance with
other sites in 450 specimens,” American Journal of Surgical
Pathology, vol. 29, no. 12, pp. 1549–1557, 2005.
[6] S. S. Foo, P. L. Mitchell, S. U. Berlangieri, C. L. Smith, and
A. M. Scott, “Positron emission tomography scanning in the
assessment of patients with lymphoma,” Internal Medicine
Journal, vol. 34, no. 7, pp. 388–397, 2004.
[7] E. E. Pakos, A. D. Fotopoulos, and J. P. A. Ioannidis, “18F-FDG
PET for evaluation of bone marrow infiltration in staging of
lymphoma: a meta-analysis,” Journal of Nuclear Medicine, vol.
46, no. 6, pp. 958–963, 2005.
[8] K. Foucar, R. W. McKenna, G. Frizzera, and R. D. Brunning,
“Bone marrow and blood involvement by lymphoma in
relationship to the Lukes-Collins classification,” Cancer, vol.
49, no. 5, pp. 888–897, 1982.
[9] M. G. Conlan, M. Bast, J. O. Armitage et al., “Bone mar-
row involvement by non-Hodgkin’s lymphoma: the clinical
significance of morphologic discordance between the lymph
node and bone marrow. Nebraska Lymphoma Study Group,”
Journal of Clinical Oncology, vol. 8, no. 7, pp. 1163–1172, 1990.
[10] C. Y. O. Wong, J. Thie, K. J. Parling-Lynch et al., “Investigating
the existence of quantum metabolic values in non-Hodgkin’s
lymphoma by F-18 FDG,” Molecular Imaging and Biology, vol.
9, no. 1, pp. 43–49, 2007.
[11] C. Y. O. Wong, D. Noujaim, H. F. Fu et al., “Time sensitivity:
a parameter reflecting tumor metabolic kinetics by variable
dual-time f-18 FDG PET imaging,” Molecular Imaging and
Biology, vol. 11, no. 4, pp. 283–290, 2009.
[12] F. Moog, M. Bangerter, J. Kotzerke, A. Guhlmann, N. Frick-
hofen, and S. N. Reske, “18-F-fluorodeoxyglucose-positron
emission tomography as a new approach to detect lymphoma-
tous bone marrow,” Journal of Clinical Oncology, vol. 16, no. 2,
pp. 603–609, 1998.
[13] G. Jerusalem, Y. Beguin, F. Najjar et al., “Positron emis-
sion tomography (PET) with 18F-fluorodeoxyglucose (18F-
FDG) for the staging of low-grade non-Hodgkin’s lymphoma
(NHL),” Annals of Oncology, vol. 12, no. 6, pp. 825–830, 2001.
6 International Journal of Molecular Imaging
[14] D. Fustera, S. Chianga, C. Andreadisb et al., “Can [18F]Fluo-
rodeoxyglucose positron emission tomography imaging com-
plement biopsy results from the iliac crest for the detection
of bone marrow involvement in patients with malignant
lymphoma?” Nuclear Medicine Communications, vol. 27, pp.
11–15, 2006.
[15] R. Elstrom, L. Guan, G. Baker et al., “Utility of FDG-PET
scanning in lymphoma by WHO classification,” Blood, vol.
101, no. 10, pp. 3875–3876, 2003.
[16] N. G. Schaefer, K. Strobel, C. Taverna, and T. F. Hany, “Bone
involvement in patients with lymphoma: the role of FDG-
PET/CT,” European Journal of Nuclear Medicine and Molecular
Imaging, vol. 34, no. 1, pp. 60–67, 2007.
[17] B. D. Cheson, B. Pfistner, M. E. Juweid et al., “Revised
response criteria for malignant lymphoma,” Journal of Clinical
Oncology, vol. 25, no. 5, pp. 579–586, 2007.
